Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
US5470571A · kind A · utility
47Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 24, 1990 |
| Grant date | Nov 28, 1995 |
| Priority date | — |
| Expiry date | Apr 24, 2010 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/732
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Monoclonal antibody 425 having properties particularly beneficial for anti-tumor therapy has been raised. MAb 425 antibody binds to EGF-receptors and inhibits their bioactivities. The amount of binding of the antibody to cancer cells can be increased by treatment of the cells with lymphokine preparations. Radiolabeled MAb 425 is used for treatment of EGF receptor-expressing gliomas.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.